Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

10.1038/leu.2016.186

Saved in:
Bibliographic Details
Main Authors: Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hajek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, MA
Other Authors: DEAN'S OFFICE (MEDICINE)
Format: Article
Language:English
Published: NATURE PUBLISHING GROUP 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
STEM-CELL TRANSPLANTATION
LENALIDOMIDE MAINTENANCE
RETREATMENT
INHIBITOR
Online Access:https://scholarbank.nus.edu.sg/handle/10635/229017
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Internet

https://scholarbank.nus.edu.sg/handle/10635/229017

Similar Items